Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash Flows From Operating Activities:
Loss from continuing operations	$ (66,376)	$ (118,686)
Loss from discontinued operations, net of income taxes	(39)	(227)
Net loss	(66,415)	(118,913)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	200	212
Amortization of debt discount	17	0
Stock-based compensation	7,635	12,686
Non-cash lease expense	539	1,151
Other non-cash items	88	281
Loss on disposal of manufacturing equipment	0	3,057
Loss on disposal of assets	2	0
Realized loss (gain) on sale of equity holdings	1,094	(4,580)
Unrealized loss on equity holdings	3,352	12,816
Changes in operating assets and liabilities:
Accounts receivable, net	0	66
Other receivables	431	(1,391)
Inventories	(9,373)	0
Prepaid expenses and other current assets	(617)	1,620
Other assets	976	(89)
Accounts payable and other accrued liabilities	389	4,376
Accrued payroll and benefits	(4,360)	(1,085)
Other long-term liabilities	(5,609)	654
Net cash used in operating activities	(71,651)	(89,139)
Cash Flows From Investing Activities:
Proceeds from maturities of investments	2,799	109,771
Proceeds from sale of equity holdings	2,028	4,406
Purchases of investments	(41,023)	(16,568)
Purchases of property and equipment, net	(45)	(140)
Net cash (used in) provided by investing activities	(36,241)	97,469
Cash Flows From Financing Activities:
Issuance of common shares to Hanmi Pharmaceutical Co., Ltd.	20,000	0
Proceeds from the issuance of debt, net of debt issuance costs	28,852	0
Proceeds from sale of common stock under an at-the-market sales agreement, net	26,560	52,622
Proceeds from sale of stock under our employee stock purchase plan	257	474
Proceeds from employees for exercises of stock options	0	4
Net cash provided by financing activities	75,669	53,100
Effect of exchange rates on cash and cash equivalents	(61)	(4)
Net (decrease) increase in cash and cash equivalents	(32,284)	61,426
Cash and cash equivalents—beginning of period	88,539	46,009
Cash and cash equivalents—end of period	56,255	107,435
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases	1,492	1,626
Cash paid for income taxes	0	12
Supplemental disclosures of non-cash financing activity:
Issuance of warrants in connection with debt financing	230	0
Debt issuance costs in accrued liabilities	$ 152	$ 0